Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Income Statement and Estimates

More financial data

Market Closed - Deutsche Boerse AG Other stock markets 12:20:49 09/06/2026 +03			5-day change	1st Jan Change
0.4400 ^EUR	+1.85%		0.00%	-43.88%

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	2.88M 3.28M 2.65M 2.48M 4.65M 309M 4.75M 31.87M 12.33M 153M 12.32M 12.05M 530M	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	3.96M 4.51M 3.65M 3.41M 6.4M 426M 6.54M 43.84M 16.96M 210M 16.95M 16.58M 730M	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	98.11%	Yield 2023 *	-	Yield 2024	-

11-03	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/04/25	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/10/24	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/04/24	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/03/24	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/11/23	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/10/23	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/04/23	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/03/23	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/12/22	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/12/22	Twitter to shut down newsletter product Revue next year	RE
06/12/22	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
05/10/22	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

03-03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
02-25	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
12-10	Klarsen : ALKLA-Attribution gratuite de BSA	PU
12-09	Klarsen : ALKLA-ACTIVITE 3T2025	PU
11-27	Klarsen : ALKLA-Résultat augmentation de capital	PU

Klarsen Stock Deutsche Boerse AG

Stocks

4YA

FR0011038348

IT Services & Consulting

Valuation: Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases: Klarsen

News in other languages: Klarsen

Quotes and Performance

Course Extremes

Managers and Directors: Klarsen

Other IT Services & Consulting

Financials

Company Profile

Income Statement and Estimates

06-09	Klarsen : ALKLA – Report des résultats trimestriels et date de publication des comptes annuels – 9 Juin 2026
06-01	Klarsen : Information réglementée – 2026
05-06	Klarsen : Report de la publication des comptes annuels 2025
05-05	Klarsen : ALKLA – Ouverture d’une procédure de redressement judiciaire auprès du Tribunal judiciaire de Strasbourg pour la filiale ITL – Soutien financier de l’actionnaire principal – 05 Mai 2026
05-05	KLARSEN : Ouverture d’une procédure de redressement judiciaire auprès du Tribunal judiciaire de Strasbourg pour la filiale ITL

1 day	+1.85%
Current month	-29.49%
1 month	+10.00%
3 months	-41.80%
6 months	-44.86%
Current year	-43.88%

1 month	0.43	0.62
Current year	0.2	1.07
1 year	0.2	1.07
3 years	0.2	3.83
5 years	0.2	3.83
10 years	0.2	4.14

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Jean-Luc Rivière BRD	Director/Board Member	-	26/06/2012
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	+1.85%	0.00%	-	-	1.44M
IBM	+5.17%	+9.04%	-6.24%	+105.25%	255B
SNOWFLAKE INC.	+9.65%	+7.18%	+11.84%	+40.64%	86.29B
TATA CONSULTANCY SERVICES LTD.	-0.68%	-1.43%	-39.13%	-34.49%	80.34B
ACCENTURE PLC	+2.51%	+0.78%	-56.35%	-57.12%	78.93B
RELX PLC	-0.25%	-0.59%	-40.01%	-8.66%	55.03B
INFOSYS LIMITED	-1.46%	-0.97%	-35.25%	-18.60%	44.67B
FUJITSU LIMITED	+0.38%	-0.37%	-7.60%	+75.91%	34.33B
HCL TECHNOLOGIES LIMITED	-1.19%	-2.74%	-36.13%	-5.92%	31.57B
NEC CORPORATION	+1.01%	+1.04%	-9.43%	+178.80%	31.14B
Average	+1.70%	-0.08%	-24.25%	+30.65%	77.51B
Weighted average by Cap.	+3.19%	+2.97%	-19.54%	+42.69%

	2023	2024
Net sales	5.03M 5.73M 4.63M 4.34M 8.13M 541M 8.3M 55.68M 21.55M 267M 21.52M 21.05M 927M	6.31M 7.2M 5.82M 5.45M 10.21M 679M 10.42M 69.92M 27.05M 336M 27.03M 26.44M 1.16B
Net income	2.75M 3.14M 2.54M 2.37M 4.45M 296M 4.54M 30.48M 11.79M 146M 11.78M 11.52M 507M	-47.76K -54.48K -44.03K -41.22K -77.29K -5.14M -78.9K -529K -205K -2.54M -205K -200K -8.81M
Net Debt	-634K -724K -585K -548K -1.03M -68.26M -1.05M -7.03M -2.72M -33.74M -2.72M -2.66M -117M	1.08M 1.23M 996K 933K 1.75M 116M 1.79M 11.97M 4.63M 57.47M 4.63M 4.53M 199M